Trial Profile
A Phase III, Randomized, Single Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Administered to Subjects Previously Vaccinated in Trials V118_05 and V118_05E1
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2017
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine quadrivalent-Seqirus (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Novartis Pharma A.G.
- 05 Oct 2017 New trial record